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ABSTRACT 
Introduction. Neuromodulation devices have known a great progress in the past 
years being used in treatment of drug resistant neurological diseases such as 
epilepsies and migraines. A neuromodulation device can stimulate profound or 
superficial neural pathways in order to balance chronic drug-resistant disorders that 
involve disturbances of cellular electrical potentials.  
Material. Cranial neuromodulation devices implants used until now usually 
determined skull irregularities, implant site infection, resorption of the bone flap or 
osteomyelitis. In order to solve these problems, it was needed a customized cranial 
implant that integrates the neuromodulation device. 
We report the first description of a fully integrated neuromodulation device within a 
customized cranial implant, publicised in 2018 by Gordon et al., that demonstrates 
the utility of a computerized neurostimulation device combined with clear custom-
designed cranial implant. 
Conclusion. The new approach of neurotechnology confines a better solution for 
neuroimplants devices with less follow-up complications and great patient’s 
satisfaction. 
 
 
INTRODUCTION  
Neuromodulation devices stimulate profound or superficial neural 
pathways in order to balance chronic drug-resistant disorders that 
involve disturbances of cellular electrical potentials, such as epilepsies 
and migraines. Most of the cranial neuromodulation device implants 
used until now had adverse reactions like skull irregularities, implant 
site infection, resorption of the bone flap or osteomyelitis [1-5]. 
 
MATERIAL 
We report the first description of a fully integrated neuromodulation 
device within a customized cranial implant, publicised in 2018 by 
Gordon et al., that demonstrates the utility of a computerized 
neurostimulation device combined with clear custom-designed cranial 
implant.
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Modern day treatment for drug resistant neuro-
logical diseases has known a great progress during 
past years. In 2018, Gordon et al. from Johns Hopkins 
Hospital, Maryland, USA, reported first in-human 
experience using a neuromodulation device within a 
cranial implant. The neuromodulation was used 
before in drug resistant epilepsies and migraines 
[1,2]. It is well known that one in three patients with 
focal seizures develops a drug resistant form of 
epilepsy. Patients with focal seizures who have failed 
multiple drug associated treatment that do not fit 
neurosurgical approach need vagus nerve stimu-
lation or responsive neurostimulation [1,3,4,5]. 
The responsive neurostimulation system, ap-
proved by the FDA in 2013, is used for patients that 
have drug resistant epilepsy with less than 2 
epileptogenic foci and it has a cortical stimulator that 
detects and respond to the electroencephalographic 
events [1,6]. Even though it has a great efficacy, there 
has been reported a lot of complications about the 
montage of the device, such as: scalp dehiscence, 
device exposure, contamination of hardware, 
infections, contour irregularities, bone flap 
osteomyelitis, visual deformities that affect quality of 
patient’s life [1,7,8].  
In order to solve all these problems and to reduce 
the number of re-interventions that increases the 
risk of infections, Gordon et al. started to plan a new 
improved implant design.  They changed the opaque 
material used before with a transparent one for a 
better visibility and accuracy of the positioning to 
avoid the electrocorticographic signal interference. 
All the components of the device were integrated 
below the implant as an incorporated piece, fact that 
prevents the obvious deformities of the skull and 
scalp and the migration of the device into the scalp 
[1, 9-11]. 
 
DISCUSSION 
Gordon et al. used a 54 years old drug resistant 
epilepsy patient who needed responsive 
neurostimulation device with cranioplasty. A 
multidisciplinary team formed by neurosurgeons 
and plastic surgeons produced a perfect size 3D 
printed mold of the patient’s skull that was 
computer-laser modified with a 5-axis robot laser 
cutter and after that presterilised [1,12,13]. The 
responsive neurostimulation device with the leads 
were placed under the clear cranial implant making 
possible a perfect visualization of the connections 
and possible inadvertent device interference. The 
patient was fully recovered with no complications. 
This was the first description of a fully integrated 
neuromodulation device within a customized cranial 
implant [1,13,14]. 
The method allows the avoidance of visible 
irregularities, scalp dehiscence, device extrusion and 
lead migration identified as complications of 
standard procedures above skull. The technology of 
cranial implants is expected to develop and treat 
other brain pathologies such as tumours and 
movement disorders and maybe it can be implicated 
more in intelligent cognition devices for memory 
diseases [1]. 
 
CONCLUSION 
We can make a conclusion that the new approach of 
neurotechnology confines a better solution for 
neuroimplants devices with less follow-up compli-
cations and great patient’s satisfaction. It is a great 
demonstration that can inspire new research in 
other brain pathologies that can use computerized 
neurostimulation device combined with clear 
custom-designed cranial implant [1, 15, 16]. 
 
 
REFERENCES 
1. Gordon CR, Santiago GF, Huang J, Bergey GK, Liu S., 
Armand M, Brem H, Anderson WS; First In-Human 
Experience With Complete Integration of 
Neuromodulation Device Within a Customized 
Cranial Implant, Operative Neurosurgery, Volume 
15, Issue 1, 1 July 2018, Pages 39–45, 
https://doi.org/10.1093/ons/opx210 
2. Kwan P, Brodie MJ. Early identification of refractory 
epilepsy. N Engl J Med. 2000;342(5):314-319. 
3. Morris GL 3rd, Gloss D, Buchhalter J, Mack KJ, 
Nickels K, Harden C. Evidence-based guideline 
update: vagus nerve stimulation for the treatment 
of epilepsy: report of the Guideline Development 
Subcommittee of the American Academy of 
Neurology. Neurology. 2013;81(16):1453-1459. 
4. Collins KL, Lehmann EM, Patil PG. Deep brain 
stimulation for movement disorders. Neurobiol Dis. 
2010;38(3):338-345. 
5. Fisher RS, Velasco AL. Electrical brain stimulation for 
epilepsy. Nat Rev Neurol. 2014;10(5):261-270. 
6. RNS System in Epilepsy Study GroupMorrell MJ. 
Responsive cortical stimulation for the treatment of 
medically intractable partial epilepsy. Neurology. 
2011;77(13):1295-1304. 
7. Lopez J, Zhong SS, Sankey EW, et al. Time interval 
reduction for delayed implant-based cranioplasty 
 33 Neuromodulation Devices Nowadays 
reconstruction in the setting of previous bone flap 
osteomyelitis. Plast Reconstr Surg. 2016; 137(2): 
394e-404e. 
8. Berli JU, Thomaier L, Zhong S, et al. Immediate 
single-stage cranioplasty following calvarial 
resection for benign and malignant skull neoplasms 
using customized craniofacial implants. J Craniofac 
Surg. 2015;26(5):1456-1462. 
9. Wei Z, Gordon CR, Bergey GK, Sacks JM, Anderson 
WS. Implant site infection and bone flap 
osteomyelitis associated with the NeuroPace 
responsive neurostimulation system. World 
Neurosurg. 2016;88(687): e1-e6. 
10. Heck CN, King-Stephens D, Massey AD, et al. Two-
year seizure reduction in adults with medically 
intractable partial onset epilepsy treated with 
responsive neurostimulation: final results of the RNS 
System Pivotal trial. Epilepsia. 2014;55(3):432-441. 
11. Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term 
treatment with responsive brain stimulation in 
adults with refractory partial seizures. Neurology. 
2015;84(8):810-817. 
12. Zhong S,Huang GJ, Susarla SM, Swanson EW,Huang 
J, Gordon CR. Quantitative analysis of dual-purpose, 
patient-specific craniofacial implants for correction 
of temporal deformity. Neurosurgery. 
2015;11(Suppl 2):220-229; discussion 229. 
13. Liu J, Fang J, Murphy R, Gordon CR, Armand M. 
Design and development of 5-axis cranial implant 
laser cutting system. In: Proceedings of the ASME 
2017 International Design Engineering Technical 
Conferences & Computers and Information in 
Engineering Conference. IDETC/CIE; 2017. 
14. Alambeigi F, Sefati S, Murphy R, Armand M, Gordon 
CR, Liu S. A cutting machine for resizing raw implants 
during surgery. WO 2016 086049. U.S. International 
Patent application number PCT/US2015/062516. 
Published February 6, 2016. 
15. Anderson WS, Kossoff EH, Bergey GK, Jallo GI. 
Implantation of a responsive neurostimulator device 
in patients with refractory epilepsy. Neurosurg 
Focus. 2008;25(3): E12. 
16. Gordon C, Bryndza JR, Basic T. Patient-specific 
craniofacial implants. Issued Patent 20160081805. 
Published March 24, 2016. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
